Bristol-Myers Squibb

Investors

Bristol-Myers Squibb

 

 

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Their medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis. Over the past decade, Bristol-Myers Squibb has delivered 14 new products to patients with serious diseases, four of which are biologic products. Additional biologic compounds, as well as scores of other investigational medicines, are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive R&D pipelines in the industry. As a BioPharma leader, they believe what sets them apart is a commitment to helping patients prevail over serious diseases and their focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything Bristol-Myers Squibb does: making a difference in the lives of patients.

...

Lee H. Evans, Executive Director & Head, North America Capability Center & Global Capability Center Operations

With over 20 years of experience across a variety of life sciences and biopharmaceutical enterprises, Lee H. Evans is responsible for leadership of the effort to establish a multi-function capability center for North America at Bristol-Myers Squibb’s newest location in Tampa. He oversees strategy, organizational design, vision, culture and overall operations for this new corporate knowledge center. Evans joined Bristol-Myers Squibb in 2009 as director of Global Development Informatics, with responsibilities across areas of Global Development, Medical Affairs, Global Pharmacovigilance and Epidemiology. In 2011, he became group director and head of R&D Information and Analytics Sciences. Evans has degrees in both biological engineering and economics from North Carolina State University. He has lectured in the Duke University Healthcare Sector MBA program on technology topics and has testified regarding emerging technology issues before the Commissioner of the FDA.

Investors

Bristol-Myers Squibb

 

 

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Their medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis B, HIV/AIDS and rheumatoid arthritis. Over the past decade, Bristol-Myers Squibb has delivered 14 new products to patients with serious diseases, four of which are biologic products. Additional biologic compounds, as well as scores of other investigational medicines, are advancing through the development pipeline. Bristol-Myers Squibb is recognized as having one of the most productive R&D pipelines in the industry. As a BioPharma leader, they believe what sets them apart is a commitment to helping patients prevail over serious diseases and their focus on finding innovative medicines to combat those diseases. Generating new ideas and thinking differently are at the heart of everything Bristol-Myers Squibb does: making a difference in the lives of patients.

...
...

Lee H. Evans, Executive Director & Head, North America Capability Center & Global Capability Center Operations

With over 20 years of experience across a variety of life sciences and biopharmaceutical enterprises, Lee H. Evans is responsible for leadership of the effort to establish a multi-function capability center for North America at Bristol-Myers Squibb’s newest location in Tampa. He oversees strategy, organizational design, vision, culture and overall operations for this new corporate knowledge center. Evans joined Bristol-Myers Squibb in 2009 as director of Global Development Informatics, with responsibilities across areas of Global Development, Medical Affairs, Global Pharmacovigilance and Epidemiology. In 2011, he became group director and head of R&D Information and Analytics Sciences. Evans has degrees in both biological engineering and economics from North Carolina State University. He has lectured in the Duke University Healthcare Sector MBA program on technology topics and has testified regarding emerging technology issues before the Commissioner of the FDA.